Ferring

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Retrieved on: 
Monday, December 11, 2023

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

Key Points: 
  • Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
  • View the full release here: https://www.businesswire.com/news/home/20231210383233/en/
    The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
  • “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients.
  • PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals.

Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members

Retrieved on: 
Thursday, November 9, 2023

With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.

Key Points: 
  • With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.
  • Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
  • Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.
  • www.polepharma.com
    Hervé Affagard, President of Alliance Promotion Microbiote states "We are thrilled to extend a warm welcome to Ferring Pharmaceuticals, Pelican Health, and Polepharma as they join our microbiome-focused association.

Bladder Cancer Advocacy Network Announces Exclusive National Presenting Sponsorship by Ferring Pharmaceuticals for 2024 Walks to End Bladder Cancer

Retrieved on: 
Monday, October 2, 2023

BETHESDA, Md., Oct. 2, 2023 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer. This landmark collaboration marks a significant milestone in the fight against bladder cancer and promises to raise awareness and funds to support bladder cancer research, patient education and support, and advocacy.

Key Points: 
  • BETHESDA, Md., Oct. 2, 2023 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer.
  • "We are delighted and grateful to welcome Ferring Pharmaceuticals as our National Presenting Sponsor for the 2024 Walks to End Bladder Cancer," said Andrea Maddox-Smith, CEO of BCAN.
  • BCAN's Walks to End Bladder Cancer are signature awareness-building events hosted in multiple cities in the United States during May, Bladder Cancer Awareness Month.
  • The Walks include thousands of participants united in support of bladder cancer patients and families and help raise awareness of bladder cancer, the sixth-most diagnosed cancer in America.

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

Retrieved on: 
Thursday, August 24, 2023

Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone.

Key Points: 
  • Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone.
  • The royalty is expected to end in the early to mid-2030s.
  • It also highlights its significant potential as a key growth driver for Ferring, and our commitment to Uro-Oncology,” said Jean-Frédéric Paulsen, Executive Chairman of Ferring Pharmaceuticals.
  • “Adstiladrin is the first gene therapy in our diversified royalty portfolio.

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Retrieved on: 
Tuesday, April 18, 2023

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.

Key Points: 
  • Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.
  • View the full release here: https://www.businesswire.com/news/home/20230418005217/en/
    Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health (Photo: Business Wire)
    BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health.
  • The strategic collaboration builds on Ferring’s engagement with BII’s Women’s Health Initiative through Ferring’s membership on the BII Women’s Health Innovation Panel.
  • We are pleased to collaborate even closer with Ferring to make it happen,” says Trine Bartholdy, Chief Innovation Officer at the BioInnovation Institute.

INVO Provides Preliminary Update on FY2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023

SARASOTA, Fla., March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SARASOTA, Fla., March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022.
  • Gross operating expenses, inclusive of non-cash charges, are expected to be comparable to the third quarter of 2022.
  • "Consummation of our planned Wisconsin Fertility Institute acquisition is expected to provide INVO with the ability to accelerate our business plan and significantly improve our financial profile.
  • We look forward to hosting our regular investor call within the next two weeks and to provide additional details on our financial results, the acquisition and INVO's prospects and plans."

Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults

Retrieved on: 
Tuesday, February 14, 2023

Ferring Pharmaceuticals today announced that REBYOTA™ (fecal microbiota, live – jslm) is now available in the United States (U.S.).

Key Points: 
  • Ferring Pharmaceuticals today announced that REBYOTA™ (fecal microbiota, live – jslm) is now available in the United States (U.S.).
  • REBYOTA is the first and only microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
  • REBYOTA is a single-dose treatment that is administered in minutes during one visit at the doctor’s office.
  • The REBYOTA CONNECT program provides guidance to healthcare providers about access services, as well as information about co-pay and patient assistance programs.

Ferring Pharmaceuticals Announces the Launch of FertilityWise - a New, On-Demand E-Learning Program for Fertility Clinic Staff

Retrieved on: 
Friday, October 21, 2022

This new offering underscores Ferring's commitment to helping educate healthcare providers by compiling innovative, evidence-based content related to fertility care into easy-to-access modules.

Key Points: 
  • This new offering underscores Ferring's commitment to helping educate healthcare providers by compiling innovative, evidence-based content related to fertility care into easy-to-access modules.
  • PARSIPPANY, N.J., Oct. 21, 2022 /PRNewswire/ -- Ferring Pharmaceuticals U.S. today announced the launch of FertilityWise, a digital, on-demand series of e-learning modules developed specifically for fertility nurses and advanced practice providers.
  • Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
  • Nearly half of fertility patients in the US, Canada, and UK use EngagedMD's eLearn and eSign tools during their fertility journey.

Ferring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market Trends at ASRM 2022 Scientific Congress & Expo

Retrieved on: 
Wednesday, October 19, 2022

PARSIPPANY, N.J., Oct. 19, 2022 /PRNewswire/ -- Ferring Pharmaceuticals today announced that it will presenting a company-sponsored abstract highlighting an in-depth analysis of future trends in the Assisted Reproductive Technology (ART) market and will also host a product theater at the American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo taking place October 22-26 in Anaheim, CA.

Key Points: 
  • PARSIPPANY, N.J., Oct. 19, 2022 /PRNewswire/ -- Ferring Pharmaceuticals today announced that it will presenting a company-sponsored abstract highlighting an in-depth analysis of future trends in the Assisted Reproductive Technology (ART) market and will also host a product theater at the American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo taking place October 22-26 in Anaheim, CA.
  • Ferring's data presentation leveraged national summaries of U.S. gonadotropin utilization as compared to data provided by the Centers for Disease Control (CDC), to provide a forecast of future trends in the ART market.
  • This research provides interesting insights about anticipated future treatment demand and helps to ensure availability of resources for people building their families.
  • In the United States, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics.

Ferring Introduces Fertility Outreach, a Text-based Platform Providing Aspiring Parents with Access to a Live Fertility Coach

Retrieved on: 
Tuesday, October 18, 2022

Through Fertility Outreach, Ferring aims to address the very real and sometimes overlooked aspects of a fertility journey that aspiring parents experience and may need additional support navigating.

Key Points: 
  • Through Fertility Outreach, Ferring aims to address the very real and sometimes overlooked aspects of a fertility journey that aspiring parents experience and may need additional support navigating.
  • With Fertility Outreach, aspiring parents are now just a text message away to connecting with expert coaches to receive personalized and empowering guidance and information."
  • Fertility Outreach is part of Fertility Out Loud, a platform and social community that Ferring launched in 2021 to help improve access to care for all aspiring parents.
  • Robyn is a community-driven digital platform that provides access to a network of integrative parental wellness tools, resources, and specialists.